Current status of artificial intelligence methods for skin cancer survival analysis: a scoping review

Front Med (Lausanne). 2024 Apr 22:11:1243659. doi: 10.3389/fmed.2024.1243659. eCollection 2024.

Abstract

Skin cancer mortality rates continue to rise, and survival analysis is increasingly needed to understand who is at risk and what interventions improve outcomes. However, current statistical methods are limited by inability to synthesize multiple data types, such as patient genetics, clinical history, demographics, and pathology and reveal significant multimodal relationships through predictive algorithms. Advances in computing power and data science enabled the rise of artificial intelligence (AI), which synthesizes vast amounts of data and applies algorithms that enable personalized diagnostic approaches. Here, we analyze AI methods used in skin cancer survival analysis, focusing on supervised learning, unsupervised learning, deep learning, and natural language processing. We illustrate strengths and weaknesses of these approaches with examples. Our PubMed search yielded 14 publications meeting inclusion criteria for this scoping review. Most publications focused on melanoma, particularly histopathologic interpretation with deep learning. Such concentration on a single type of skin cancer amid increasing focus on deep learning highlight growing areas for innovation; however, it also demonstrates opportunity for additional analysis that addresses other types of cutaneous malignancies and expands the scope of prognostication to combine both genetic, histopathologic, and clinical data. Moreover, researchers may leverage multiple AI methods for enhanced benefit in analyses. Expanding AI to this arena may enable improved survival analysis, targeted treatments, and outcomes.

Keywords: artificial intelligence; deep learning; machine learning; natural language processing; oncology; skin cancer; supervised learning; unsupervised learning.

Publication types

  • Review

Grants and funding

This work was supported by the Columbia University Herbert Irving Comprehensive Cancer Center Inter/Intra-Programmatic Pilot Program.